entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 19:27:03 - browse：257

inflamed intestine on a dark blue background — biotech coverage from STAT — Adobe

What happens after you close a nearly $11 billion acquisition?

Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future.

Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer. This “summer of discovery,” as McKenna called it, brought him back to the immune system. Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Pharma patents targeted by Biden in move to slash drug prices

WSS

Why doctors need education on FDA device approval process

EU regulator recommends expanding Mounjaro approval to obesity

eGenesis tests gene

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Eli Lilly, Pfizer, and others want in on the online prescription market

Teach medical students about patients with intellectual disabilities

hotspot

entertainment

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Parkinson’s finding may lead to tests and, someday, treatments

How one medical school became remarkably diverse

Biotech venture capitalists face new demands from investors

The cancer drug shortage isn’t new — and neither are the solutions

FDA approves world's first CRISPR

Hepatitis C has a cure — but many Americans still lack access to it

How digital therapeutics firms are pivoting after Pear's bankruptcy

Drug repurposing or repositioning? The language matters

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

explore

FDA approves world's first CRISPR

Why sickle cell disease is getting the first CRISPR treatment

Pharma patents targeted by Biden in move to slash drug prices

NIH director takes cautious approach to Biden drug pricing priority

CMS should re

Medicare Advantage today, explained in one chart

Wikipedia

leisure time

focus

explore